Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27915744 | 0.83 | SIRT3 (0.47) | SIRT3TDP1RIPK2MAPK14RAB9A | |
| SCHEMBL971001 | 0.82 | MAPK14 (0.72) | RIPK2MAPK14RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30147284 | 0.81 | SIRT3 (0.50) | SIRT3TDP1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL31341686 | 0.80 | RIPK2 (0.52) | SIRT3TDP1RIPK2MAPK14RAB9A | |
| SCHEMBL8029733 | 0.80 | RIPK2 (0.52) | RIPK2MAPK14RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1457388 | 0.80 | SIRT3 (0.41) | SIRT3TDP1RIPK2MAPK14RAB9A | |
| SCHEMBL8029740 | 0.80 | RIPK2 (0.49) | SIRT3TDP1RIPK2MAPK14RAB9A | |
| SCHEMBL8049319 | 0.78 | RIPK2 (0.50) | RIPK2MAPK14RAB9ASMN1; SMN2LMNA | |
| SCHEMBL8049323 | 0.78 | SCN9A (0.54) | RIPK2MAPK14RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1691837 | 0.77 | MAPK14 (0.58) | RIPK2MAPK14RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217602-B1 | 1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2018-08-29 | — | — | EP | disclosed |
| EP-2603511-B1 | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-3053924-A1 | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-9328120-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| EP-2675807-B1 | 6-CYCLOBUTYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-04-22 | — | — | EP | disclosed |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-8912201-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8822479-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822479-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822479-B2 | 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| EP-2298773-A1 | 6-Cyclomethyl and 6-alkylmethyl substituted pyrazolopyrimidines | Boehringer Ingelheim International GmbH (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065730-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN | 2011-03-17 | — | — | US | disclosed |
| US-20110065730-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN | 2011-03-17 | — | — | US | disclosed |
| US-20110065730-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | HENDRIX MARTIN | 2011-03-17 | — | — | US | disclosed |
| WO-2011018495-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | WO | disclosed |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20070105876-A1 | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105876-A1 | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105876-A1 | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2004099211-A1 | 6-CYCLYLMETHYL- AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE1C | SIRT3 2837/4885TDP1 29/4885RIPK2 4088/4885 |
| US-20110065730-A1 | 6-CYCLYLMETHYL-AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLEPYRIMIDINES | GRM6, P2RX6, P2RY6 | SIRT3 767/4885TDP1 1971/4885RIPK2 1263/4885 |
| US-20070105876-A1 | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolepyrimidines | GRM6, P2RX6, P2RY6 | SIRT3 767/4885TDP1 1971/4885RIPK2 1263/4885 |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE2A | SIRT3 3437/4885TDP1 139/4885RIPK2 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.